Pain killers: the interplay between nonsteroidal anti-inflammatory drugs and Clostridioides difficile infection

Curr Opin Microbiol. 2022 Feb:65:167-174. doi: 10.1016/j.mib.2021.11.011. Epub 2021 Dec 8.

Abstract

Clostridioides difficile is one of the leading causes of nosocomial infections worldwide. Increases in incidence, severity, and healthcare cost associated with C. difficile infection (CDI) have made this pathogen an urgent public health threat worldwide. The factors shaping the evolving epidemiology of CDI and impacting clinical outcomes of infection are not well understood, but involve tripartite interactions between the host, microbiota, and C. difficile. In addition to this, emerging data suggests an underappreciated role for environmental factors, such as diet and pharmaceutical drugs, in CDI. In this review, we discuss the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and eicosanoids in CDI.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Clostridioides
  • Clostridioides difficile* / genetics
  • Clostridium Infections* / drug therapy
  • Humans
  • Pain

Substances

  • Anti-Inflammatory Agents, Non-Steroidal